NCR1 and lymphoma: For instance, NKp46-deficient mice exhibit impaired tumour control in lymphoma and melanoma models (101–104), while reduced NKp30 and NKp46 expression in patients with leukaemia or cervical cancer correlates with poorer outcomes (105–107).